Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles from USA
Based on 2,520 articles since 2006

These are the 2520 published articles about Crohn Disease that originated from USA during 2006-2015.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. 2015

Pennazio, Marco / Spada, Cristiano / Eliakim, Rami / Keuchel, Martin / May, Andrea / Mulder, Chris J / Rondonotti, Emanuele / Adler, Samuel N / Albert, Joerg / Baltes, Peter / Barbaro, Federico / Cellier, Christophe / Charton, Jean Pierre / Delvaux, Michel / Despott, Edward J / Domagk, Dirk / Klein, Amir / McAlindon, Mark / Rosa, Bruno / Rowse, Georgina / Sanders, David S / Saurin, Jean Christophe / Sidhu, Reena / Dumonceau, Jean-Marc / Hassan, Cesare / Gralnek, Ian M. ·Division of Gastroenterology, San Giovanni Battista University Teaching Hospital, Turin, Italy. · Digestive Endoscopy Unit, Catholic University, Rome, Italy. · Department of Gastroenterology, Chaim Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University Tel-Hashomer, Israel. · Klinik für Innere Medizin, Bethesda Krankenhaus Bergedorf, Hamburg, Germany. · Department of Medicine II, Sana Klinikum, Offenbach, Germany. · Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands. · Gastroenterology Unit, Ospedale Valduce, Como, Italy. · Division of Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel. · Department of Medicine I, Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Service d'Hépato-gastro-entérologie, Paris, France. · Medizinische Klinik, Evangelisches Krankenhaus, Düsseldorf, Germany. · Department of Hepato-Gastroenterology, Nouvel Hôpital Civil, University Hospital of Strasbourg, Strasbourg, France. · Royal Free Unit for Endoscopy and Centre for Gastroenterology, The Royal Free Hospital and University College London, London, UK. · Department of Medicine B, University of Münster, Münster, Germany. · Institute of Gastroenterology and Liver Diseases, Ha'emek Medical Center Afula, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology Haifa, Israel. · Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. · Gastroenterology Department, Centro Hospitalar do Alto Ave, Guimarães, Portugal. · Clinical Psychology Unit, Department of Psychology, University of Sheffield. · Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France. · Gedyt Endoscopy Center, Buenos Aires, Argentina. ·Endoscopy · Pubmed #25826168.

ABSTRACT: This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Guideline was also reviewed and endorsed by the British Society of Gastroenterology (BSG). It addresses the roles of small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders. Main recommendations 1 ESGE recommends small-bowel video capsule endoscopy as the first-line investigation in patients with obscure gastrointestinal bleeding (strong recommendation, moderate quality evidence). 2 In patients with overt obscure gastrointestinal bleeding, ESGE recommends performing small-bowel capsule endoscopy as soon as possible after the bleeding episode, optimally within 14 days, in order to maximize the diagnostic yield (strong recommendation, moderate quality evidence). 3 ESGE does not recommend the routine performance of second-look endoscopy prior to small-bowel capsule endoscopy; however whether to perform second-look endoscopy before capsule endoscopy in patients with obscure gastrointestinal bleeding or iron-deficiency anaemia should be decided on a case-by-case basis (strong recommendation, low quality evidence). 4 In patients with positive findings at small-bowel capsule endoscopy, ESGE recommends device-assisted enteroscopy to confirm and possibly treat lesions identified by capsule endoscopy (strong recommendation, high quality evidence). 5 ESGE recommends ileocolonoscopy as the first endoscopic examination for investigating patients with suspected Crohn's disease (strong recommendation, high quality evidence). In patients with suspected Crohn's disease and negative ileocolonoscopy findings, ESGE recommends small-bowel capsule endoscopy as the initial diagnostic modality for investigating the small bowel, in the absence of obstructive symptoms or known stenosis (strong recommendation, moderate quality evidence).ESGE does not recommend routine small-bowel imaging or the use of the PillCam patency capsule prior to capsule endoscopy in these patients (strong recommendation, low quality evidence). In the presence of obstructive symptoms or known stenosis, ESGE recommends that dedicated small bowel cross-sectional imaging modalities such as magnetic resonance enterography/enteroclysis or computed tomography enterography/enteroclysis should be used first (strong recommendation, low quality evidence). 6 In patients with established Crohn's disease, based on ileocolonoscopy findings, ESGE recommends dedicated cross-sectional imaging for small-bowel evaluation since this has the potential to assess extent and location of any Crohn's disease lesions, to identify strictures, and to assess for extraluminal disease (strong recommendation, low quality evidence). In patients with unremarkable or nondiagnostic findings from such cross-sectional imaging of the small bowel, ESGE recommends small-bowel capsule endoscopy as a subsequent investigation, if deemed to influence patient management (strong recommendation, low quality evidence). When capsule endoscopy is indicated, ESGE recommends use of the PillCam patency capsule to confirm functional patency of the small bowel (strong recommendation, low quality evidence). 7 ESGE strongly recommends against the use of small-bowel capsule endoscopy for suspected coeliac disease but suggests that capsule endoscopy could be used in patients unwilling or unable to undergo conventional endoscopy (strong recommendation, low quality evidence).

2 Guideline Guidelines for imaging of Crohn's perianal fistulizing disease. 2015

Ong, Eugene M W / Ghazi, Leyla J / Schwartz, David A / Mortelé, Koenraad J / Anonymous290897. ·*Department of Radiology, Division of Clinical MRI, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; †Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland; and ‡Department of Gastroenterology and Hepatology, Vanderbilt University, Nashville, Tennessee. · ·Inflamm Bowel Dis · Pubmed #25751067.

ABSTRACT: -- No abstract --

3 Guideline Guidelines for the multidisciplinary management of Crohn's perianal fistulas: summary statement. 2015

Schwartz, David A / Ghazi, Leyla J / Regueiro, Miguel / Fichera, Alessandro / Zoccali, Marco / Ong, Eugene M W / Mortelé, Koenraad J / Anonymous280897. ·*Department of Gastroenterology and Hepatology, Vanderbilt University, Nashville, Tennessee; †Department of Gastroenterology and Hepatology, University of Maryland Medical Center, Baltimore, Maryland; ‡University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; §Division of General Surgery, Department of Surgery, University of Washington Medical Center, Seattle, Washington; ‖Department of Surgery, Weill Medical College of Cornell University, New York, New York; and ¶Division of Clinical MRI, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. · ·Inflamm Bowel Dis · Pubmed #25751066.

ABSTRACT: -- No abstract --

4 Guideline Guidelines for the surgical treatment of Crohn's perianal fistulas. 2015

Fichera, Alessandro / Zoccali, Marco / Anonymous270897. ·*Section Gastrointestinal Surgery, Division of General Surgery. Department of Surgery, University of Washington Medical Center, Seattle, Washington; and †Department of Surgery, New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York. · ·Inflamm Bowel Dis · Pubmed #25738380.

ABSTRACT: -- No abstract --

5 Guideline A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. 2014

Gecse, Krisztina B / Bemelman, Willem / Kamm, Michael A / Stoker, Jaap / Khanna, Reena / Ng, Siew C / Panés, Julián / van Assche, Gert / Liu, Zhanju / Hart, Ailsa / Levesque, Barrett G / D'Haens, Geert / Anonymous2870788 / Anonymous2880788. ·Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Robarts Research Institute, Amsterdam, The Netherlands. · Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · St. Vincent's Hospital and University of Melbourne, Melbourne, Australia. · Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · Robarts Research Institute, London, Ontario, Canada University of Western Ontario, London, Ontario, Canada. · Department of Medicine and Therapeutics, Institute of Digestive Disease, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, Hong Kong. · Department of Gastroenterology, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain. · Department of Gastroenterology, University of Leuven, Leuven, Belgium. · Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. · APRG, Imperial College, London, UK IBD Unit, St. Mark's Hospital, London, UK. · Robarts Research Institute, San Diego, CA, USA Division of Gastroenterology, University of California San Diego, La Jolla, California, USA. · ·Gut · Pubmed #24951257.

ABSTRACT: OBJECTIVE: To develop a consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease (pCD), based on best available evidence. METHODS: Based on a systematic literature review, statements were formed, discussed and approved in multiple rounds by the 20 working group participants. Consensus was defined as at least 80% agreement among voters. Evidence was assessed using the modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria. RESULTS: Highest diagnostic accuracy can only be established if a combination of modalities is used. Drainage of sepsis is always first line therapy before initiating immunosuppressive treatment. Mucosal healing is the goal in the presence of proctitis. Whereas antibiotics and thiopurines have a role as adjunctive treatments in pCD, anti-tumour necrosis factor (anti-TNF) is the current gold standard. The efficacy of infliximab is best documented although adalimumab and certolizumab pegol are moderately effective. Oral tacrolimus could be used in patients failing anti-TNF therapy. Definite surgical repair is only of consideration in the absence of luminal inflammation. CONCLUSIONS: Based on a multidisciplinary approach, items relevant for fistula management were identified and algorithms on diagnosis and treatment of pCD were developed.

6 Guideline Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. 2014

Ruemmele, F M / Veres, G / Kolho, K L / Griffiths, A / Levine, A / Escher, J C / Amil Dias, J / Barabino, A / Braegger, C P / Bronsky, J / Buderus, S / Martín-de-Carpi, J / De Ridder, L / Fagerberg, U L / Hugot, J P / Kierkus, J / Kolacek, S / Koletzko, S / Lionetti, P / Miele, E / Navas López, V M / Paerregaard, A / Russell, R K / Serban, D E / Shaoul, R / Van Rheenen, P / Veereman, G / Weiss, B / Wilson, D / Dignass, A / Eliakim, A / Winter, H / Turner, D / Anonymous1480793 / Anonymous1490793. ·Department of Paediatric Gastroenterology, APHP Hôpital Necker Enfants Malades, 149 Rue de Sèvres 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 2 Rue de l'École de Médecine, 75006 Paris, France; INSERM U989, Institut IMAGINE, 24 Bd Montparnasse, 75015 Paris, France. Electronic address: frank.ruemmele@nck.aphp.fr. · Department of Paediatrics I, Semmelweis University, Bókay János str. 53, 1083 Budapest, Hungary. · Department of Gastroenterology, Helsinki University Hospital for Children and Adolescents, Stenbäckinkatu 11, P.O. Box 281, 00290 Helsinki, Finland. · Department of Paediatrics, Hospital for Sick Children, University of Toronto, 555 University Avenue, M5G 1X8 Toronto, ON, Canada. · Paediatric Gastroenterology and Nutrition Unit, Tel Aviv University, Edith Wolfson Medical Center, 62 HaLohamim Street, 58100 Holon, Israel. · Department of Paediatric Gastroenterology, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, Netherlands. · Unit of Paediatric Gastroenterology, Hospital S. João, A Hernani Monteiro, 4202-451, Porto, Portugal. · Gastroenterology and Endoscopy Unit, Istituto G. Gaslini, Via G. Gaslini 5, 16148 Genoa, Italy. · Division of Gastroenterology and Nutrition, and Children's Research Center, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. · Department of Pediatrics, University Hospital Motol, Uvalu 84, 150 06 Prague, Czech Republic. · Department of Paediatrics, St. Marien Hospital, Robert-Koch-Str.1, 53115 Bonn, Germany. · Department of Paediatric Gastroenterolgoy, Hepatology and Nutrition, Hospital Sant Joan de Déu, Paseo Sant Joan de Déu 2, 08950 Barcelona, Spain. · Department of Pediatrics, Centre for Clinical Research, Entrance 29, Västmanland Hospital, 72189 Västerås/Karolinska Institutet, Stockholm, Sweden. · Department of Gastroenterology and Nutrition, Hopital Robert Debré, 48 Bd Sérurier, APHP, 75019 Paris, France; Université Paris-Diderot Sorbonne Paris-Cité, 75018 Paris France. · Department of Gastroenterology, Hepatology and Feeding Disorders, Instytut Pomnik Centrum Zdrowia Dziecka, Ul. Dzieci Polskich 20, 04-730 Warsaw, Poland. · Department of Paediatric Gastroenterology, Children's Hospital, University of Zagreb Medical School, Klaićeva 16, 10000 Zagreb, Croatia. · Department of Paediatric Gastroenterology, Dr. von Hauner Children's Hospital, Lindwurmstr. 4, 80337 Munich, Germany. · Department of Gastroenterology and Nutrition, Meyer Children's Hospital, Viale Gaetano Pieraccini 24, 50139 Florence, Italy. · Department of Translational Medical Science, Section of Paediatrics, University of Naples "Federico II", Via S. Pansini, 5, 80131 Naples, Italy. · Paediatric Gastroenterology and Nutrition Unit, Hospital Materno Infantil, Avda. Arroyo de los Ángeles s/n, 29009 Málaga, Spain. · Department of Paediatrics 460, Hvidovre University Hospital, Kettegård Allé 30, 2650 Hvidovre, Denmark. · Department of Paediatric Gastroenterology, Yorkhill Hospital, Dalnair Street, Glasgow G3 8SJ, United Kingdom. · 2nd Department of Paediatrics, "Iuliu Hatieganu" University of Medicine and Pharmacy, Emergency Children's Hospital, Crisan nr. 5, 400177 Cluj-Napoca, Romania. · Department of Pediatric Gastroenterology and Nutrition, Rambam Health Care Campus Rappaport Faculty Of Medicine, 6 Ha'alya Street, P.O. Box 9602, 31096 Haifa, Israel. · Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen, Netherlands. · Department of Paediatric Gastroenterology and Nutrition, Children's University Hospital, Laarbeeklaan 101, 1090 Brussels, Belgium. · Paediatric Gastroenterology and Nutrition Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52625 Tel Hashomer, Israel. · Child Life and Health, Paediatric Gastroenterology, Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh EH9 1LF, United Kingdom. · Department of Medicine I, Agaplesion Markus Hospital, Wilhelm-Epstein-Str. 4, 60431 Frankfurt/Main, Gemany. · 33-Gastroenterology, Sheba Medical Center, 52621 Tel Hashomer, Israel. · Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Mass General Hospital for Children, 175 Cambridge Street, 02114 Boston, United States. · Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel. · ·J Crohns Colitis · Pubmed #24909831.

ABSTRACT: Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.

7 Guideline American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. 2013

Terdiman, Jonathan P / Gruss, Claudia B / Heidelbaugh, Joel J / Sultan, Shahnaz / Falck-Ytter, Yngve T / Anonymous4320764. ·Division of Gastroenterology, University of California, San Francisco School of Medicine, San Francisco, California. · ·Gastroenterology · Pubmed #24267474.

ABSTRACT: -- No abstract --

8 Guideline Management of Crohn's disease in adults. 2009

Lichtenstein, Gary R / Hanauer, Stephen B / Sandborn, William J / Anonymous4670627. ·Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. gary.lichtenstein@uphs.upenn.edu · ·Am J Gastroenterol · Pubmed #19174807.

ABSTRACT: Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When data that will withstand objective scrutiny are not available, a recommendation may be made based on a consensus of experts. Guidelines are intended to apply to the clinical situation for all physicians without regard to specialty. Guidelines are intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated. Given the wide range of choices in any health-care problem, the physician should select the course best suited to the individual patient and the clinical situation presented. These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee. Expert opinion is solicited from the outset for the document. The quality of evidence upon which a specific recommendation is based is as follows: Grade A: Homogeneous evidence from multiple well-designed randomized (therapeutic) or cohort (descriptive) controlled trials, each involving a number of participants to be of sufficient statistical power. Grade B: Evidence from at least one large well-designed clinical trial with or without randomization, from cohort or case-control analytic studies, or well-designed meta-analysis. Grade C: Evidence based on clinical experience, descriptive studies, or reports of expert committees. The Committee reviews guidelines in depth, with participation from experienced clinicians and others in related fields. The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time.

9 Guideline Refractory inflammatory bowel disease in children. 2008

Oliva-Hemker, M / Escher, J C / Moore, D / Dubinksy, M / Hildebrand, H / Koda, Y K L / Murch, S / Sandhu, B / Seo, J K / Tanzi, M N / Warner, B / Anonymous5740613. ·Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2631, USA. moliva@jhmi.edu · ·J Pediatr Gastroenterol Nutr · Pubmed #18664886.

ABSTRACT: -- No abstract --

10 Guideline Practice parameters for the surgical management of Crohn's disease. 2007

Strong, Scott A / Koltun, Walter A / Hyman, Neil H / Buie, W Donald / Anonymous10596. ·Fletcher Allen Health Care, 111 Colchester Avenue, Fletcher 301, Burlington, Vermont 05401, USA. · ·Dis Colon Rectum · Pubmed #17690937.

ABSTRACT: -- No abstract --

11 Editorial Cumulative Evidence That Mesenchymal Stem Cells Promote Healing of Perianal Fistulas of Patients With Crohn's Disease--Going From Bench to Bedside. 2015

Garcia-Olmo, Damian / Schwartz, David A. ·Department of Surgery (Fundacion Jimenez Diaz), Universidad Autonoma de Madrid, Madrid, Spain. Electronic address: damian.garcia@uam.es. · Inflammatory Bowel Disease Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. ·Gastroenterology · Pubmed #26311275.

ABSTRACT: -- No abstract --

12 Editorial Thalidomide Treatment of Pediatric Ulcerative Colitis: A New Use for an Old Drug. 2015

Bousvaros, Athos. ·Harvard Medical School; Inflammatory Bowel Disease Center, Division of Gastroenterology, Boston Children's Hospital, Boston, Massachusetts. ·Inflamm Bowel Dis · Pubmed #26199988.

ABSTRACT: -- No abstract --

13 Editorial Editorial: post hoc analysis of SONIC trial--authors' reply. 2015

Colombel, J-F / Cornillie, F / Bevelander, G. ·The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jean-frederic.colombel@mssm.edu. · ·Aliment Pharmacol Ther · Pubmed #25939462.

ABSTRACT: -- No abstract --

14 Editorial Predicting the Need for Imaging in IBD: Radiating Only Badness? 2015

Shah, Samir A. ·Gastroenterology Associates, Inc., 44 West River Street, Providence, RI, 02904, USA, samir@brown.edu. ·Dig Dis Sci · Pubmed #25875756.

ABSTRACT: -- No abstract --

15 Editorial Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn's disease: is colonoscopic surveillance no longer needed? 2015

Schoepfer, Alain M / Lewis, James D. ·Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois/CHUV, Lausanne, Switzerland. Electronic address: alain.schoepfer@chuv.ch. · Division of Gastroenterology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. ·Gastroenterology · Pubmed #25805423.

ABSTRACT: -- No abstract --

16 Editorial Editorial: is thalidomide a good option for patients with refractory Crohn's disease? Authors' reply. 2015

Gerich, M / Yoon, J / Vasiliauskas, E. ·Cedars Sinai Medical Center, Los Angeles, CA, USA. · ·Aliment Pharmacol Ther · Pubmed #25781039.

ABSTRACT: -- No abstract --

17 Editorial Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging. 2015

Higgins, Peter D R / Fletcher, Joel G. ·Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. · Department of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA. ·Am J Gastroenterol · Pubmed #25743712.

ABSTRACT: -- No abstract --

18 Editorial If variety is the spice of life, we need to rethink our recipe: variation in inflammatory bowel disease practice among tertiary centers. 2015

Kane, Sunanda. ·Mayo Clinic, Rochester, Minnesota. ·Clin Gastroenterol Hepatol · Pubmed #25638587.

ABSTRACT: -- No abstract --

19 Editorial Preventing postoperative recurrence of Crohn's disease: how can we improve results? 2015

Sartor, R Balfour. ·University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. ·Clin Gastroenterol Hepatol · Pubmed #25576478.

ABSTRACT: -- No abstract --

20 Editorial The Holy Grail, or only half way there? 2015

Ananthakrishnan, Ashwin N / Hanauer, Stephen B. ·Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: aananthakrishnan@mgh.harvard.edu. · Feinberg School of Medicine, Northwestern University, Chicago, Illinois. ·Gastroenterology · Pubmed #25451664.

ABSTRACT: -- No abstract --

21 Editorial Should biologic agents be stopped before surgery for inflammatory bowel disease? 2015

Zaghiyan, Karen / McGovern, Dermot / Fleshner, Phillip. ·Division of Colorectal Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA. · ·Expert Rev Gastroenterol Hepatol · Pubmed #25366845.

ABSTRACT: Despite the widespread use of anti-TNF agents for inflammatory bowel disease (IBD), the need for surgical intervention remains high. As a result, many IBD patients undergoing surgery have recently been exposed to biologic agents. There is considerable controversy regarding the potential adverse effects of biologic agents on surgical outcomes in IBD patients undergoing major colorectal surgery with studies showing conflicting results. There appears to be discordance in the systemic bioavailability of anti-TNF-α in patients with Crohn's disease (CD) versus ulcerative colitis, with greater systemic absorption in CD. In patients with CD, preoperative serum anti-TNF-α levels may help guide timing of surgery as patients with elevated serum anti-TNF-α levels appear to be at higher risk for complications. In patients with ulcerative colitis there is likely no need for stopping biologic agents before surgery as there is poor systemic bioavailability of the drug in a majority of patients.

22 Editorial Understanding Crohn's disease through genetics. 2014

Murthy, Aditya / van Lookeren Campagne, Menno. ·a Department of Immunology; Genentech Inc. ; San Francisco , CA USA. · ·Cell Cycle · Pubmed #25486463.

ABSTRACT: -- No abstract --

23 Editorial Beyond infectious disease: welcome to the era of population microbiology. 2014

Pincus, Matthew R / Pei, Zhiheng. ·SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA. Electronic address: Matthew.Pincus2@va.gov. · New York University Medical Center, 550 First Avenue, New York, NY 10016, USA. Electronic address: zhiheng.pei@va.gov. ·Clin Lab Med · Pubmed #25439278.

ABSTRACT: -- No abstract --

24 Editorial Biologics in pediatric Crohn's disease: is it time to move to an earlier therapeutic approach? 2014

Hyams, Jeffrey S. ·Division of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children's Medical Center, Professor of Pediatrics, University of Connecticut School of Medicine, 282 Washington Street, Hartford, CT 06106, USA. ·Expert Rev Clin Immunol · Pubmed #25340425.

ABSTRACT: The treatment of Crohn's disease in children has undergone a revolution in the past decade following studies that have demonstrated the efficacy of anti-TNFα agents in producing durable clinical response/remission as well as reversal of growth delay in many patients. The positioning of biologic therapy continues to be debated. Should it be reserved for children failing conventional therapy including immunomodulators or should it be used as primary therapy shortly after diagnosis in children with more severe disease likely to suffer a more complicated disease course? Risk stratification will be crucial to any therapeutic decisions and emerging data hold promise that identification of those most likely to benefit will be available in the near future.

25 Editorial Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. 2014

Moss, A C. ·Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. amoss@bidmc.harvard.edu. ·Aliment Pharmacol Ther · Pubmed #25303382.

ABSTRACT: -- No abstract --